What Is New With Extraction and Acne in September 2026? Latest FDA and dermatology sources and Key Takeaways

The biggest news for extraction and acne care in September 2026 is a shift in where the field is heading: dermatology's leading voices now argue that the visible blackheads and whiteheads extraction removes are downstream symptoms, while the real target is the invisible microcomedone forming beneath normal-looking skin. At the same time, the treatments that prevent comedones from forming became easier to get, led by the FDA's May 2026 approval of the first over-the-counter fixed-dose retinoid–benzoyl peroxide gel.

Extraction itself — the in-office removal of blackheads and whiteheads with sterilized instruments — has not changed. The American Academy of Dermatology (AAD) still positions it as a backup procedure, not a first-line therapy, and still warns against doing it at home. What has changed is the science and the shelf around it.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Official resources:

Read the official notice from Healio — Use this primary source to verify the official announcement.
Read the original report from Dermatarx — Use this primary source to review the complete report.

The FDA's big move: Epiduo goes over the counter
Where extraction fits, according to the AAD
The microcomedone research that reframes extraction
Benzoyl peroxide after the benzene scare: still cleared for use
A sponge-derived "chemical extraction" drug that won't reach pharmacies
Frequently Asked Questions

The FDA's big move: Epiduo goes over the counter

On May 22, 2026, the FDA approved Galderma's Differin Epiduo Acne Gel (adapalene 0.1% with benzoyl peroxide 2.5%) for over-the-counter sale to people 12 and older, according to Galderma's announcement. It is the first prescription-to-OTC switch of a fixed-dose retinoid–benzoyl peroxide combination, with retail availability at Walmart, Target, Ulta, and Amazon beginning in summer 2026. This matters directly for anyone considering extraction.

Adapalene is a retinoid, the drug class that normalizes how pores shed dead skin cells and prevents comedones from forming in the first place. A combination that once required a prescription visit now sits next to single-ingredient Differin on the drugstore shelf. The practical effect is a lower barrier to the "ongoing skin-care plan" dermatologists require around extraction. Removing a comedone does nothing to stop the next one; a daily retinoid–benzoyl peroxide routine does.

Where extraction fits, according to the AAD

The AAD's standing guidance on extraction is unchanged in 2026. Per the academy's page on how dermatologists treat acne, acne extraction is a procedure performed by a dermatologist using sterilized instruments, reserved for blackheads and whiteheads that fail to clear with medical acne treatment. It is explicitly not a first-line therapy, and the AAD notes that comedones return unless the patient follows an ongoing skin-care plan afterward.

The academy is equally direct about the at-home version. In its guidance on pimple popping, the AAD warns that squeezing lesions yourself can push the contents deeper into the skin, spread inflammation, and cause scarring and infection. A reasonable way to apply this in September 2026:.

Try medical treatment first — a retinoid and benzoyl peroxide, now available OTC as a combination.
Reserve professional extraction for stubborn blackheads and whiteheads that survive weeks of consistent treatment.
Skip at-home extraction tools and popping entirely, especially on inflamed (red, tender) lesions.
Keep the maintenance routine going after any extraction, or the comedones come back.

The microcomedone research that reframes extraction

A March 12, 2026 update in the journal Dermatology by Oulès and Saurat argues that the microcomedone is "not just a plug" but the root of every subsequent acne lesion. Microcomedones are microscopic blockages forming in follicles that still look like clear skin — invisible precursors of the blackheads, whiteheads, and inflamed pimples that appear weeks later. The implication for extraction is significant.

Extraction can only remove comedones that are already visible; the authors' argument makes the invisible microcomedones in non-lesional skin the strategic target for long-term acne control. Clearing what you can see leaves the pipeline of future lesions untouched. This does not make extraction useless — it removes stubborn lesions faster than waiting for treatment alone. It does mean extraction is cosmetic cleanup, while retinoid-based prevention across the whole treatment area is the intervention that changes the disease's trajectory.

Benzoyl peroxide after the benzene scare: still cleared for use

Because benzoyl peroxide anchors most anti-comedone routines, the benzene question still comes up. The FDA's testing program, released in March 2025 and still the operative guidance in 2026, found that more than 90% of 95 tested products had undetectable or extremely low benzene, as reported in Healio's coverage of the FDA findings. Six products — including specific lots of La Roche-Posay Effaclar Duo, Proactiv, SLMD, and Walgreens items — were voluntarily recalled at the retail level only, with no consumer action required beyond discarding expired product.

The AAD's consumer guidance says benzoyl peroxide remains safe to use after those findings. Its one practical instruction: store the product away from heat, because benzoyl peroxide can degrade into benzene at elevated temperatures. That means keeping tubes out of hot cars and steamy bathroom windowsills, and tossing anything past its expiration date.

A sponge-derived "chemical extraction" drug that won't reach pharmacies

One pipeline product spoke directly to extraction's mechanism and then disappeared from the FDA pathway. Dermata Therapeutics' Xyngari (DMT310), a once-weekly topical derived from freshwater sponge, uses microscopic spicules to mechanically open comedones — essentially a chemistry-set version of what extraction does by hand. It worked in trials.

In the Phase 3 STAR-1 study it met all primary endpoints, reducing inflammatory lesions by 16.8 versus 13.1 for placebo and noninflammatory lesions (comedones) by 17.3 versus 12.4. But in 2026 Dermata withdrew the drug's investigational application and pivoted to selling direct-to-consumer skincare instead of pursuing FDA approval. Anyone who saw earlier coverage of DMT310 should know it is not coming to market as an approved acne drug — the proven-and-approved route to opening comedones remains retinoids, benzoyl peroxide, and in-office extraction.

Frequently Asked Questions

Can I do extractions at home if I buy professional-style tools?

The AAD advises against it. Squeezing lesions can push contents deeper, spread inflammation, and cause scarring and infection; extraction belongs in a dermatologist's office with sterilized instruments.

Do I still need a prescription for a retinoid plus benzoyl peroxide combination?

No. As of the FDA's May 22, 2026 approval, Differin Epiduo Acne Gel (adapalene 0.1%/benzoyl peroxide 2.5%) is sold over the counter to people 12 and older.

Will extraction keep my skin clear on its own?

No. The AAD says comedones return after extraction unless you follow an ongoing skin-care plan, and 2026 research points to invisible microcomedones — which extraction cannot reach — as the source of future lesions.